AbbVie concludes acquisition of Aliada Therapeutics

Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system (CNS).

"Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age," said Dawn Carlson, M.D., M.P.H., vice president, neuroscience development at AbbVie. "With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform."

Alzheimer's disease is a progressive neurodegenerative disorder that affects the brain, leading to cognitive decline, memory loss, and changes in behavior and personality. It is the most common cause of dementia, accounting for 60-80% of cases.

Read also: AbbVie seeks USFDA accelerated approval for telisotuzumab vedotin for previously treated non small cell lung cancer

Medical Dialogues team had earlier reported that AbbVie had received marketing authorization from the European Commission (EC) for ELAHERE (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. ELAHERE is a folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland.